|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
There are three main areas in which advances in tabletting will be discussed in this article:
Measuring and understanding the behaviour of materials during compression
Excipients
The impact of regulatory authorities
The Beginnings of Tabletting
Arabian manuscripts from the latter half of the 10th Century have been discovered which describe 'tablet moulds' formed by engraving hollow impressions in two facing pieces of ebony, wood, ivory or stone.
In the UK, in 1843, William Brockendon was granted patent number 9977 "For the shaping of pills, lozenges and black lead by pressure in a die". Prior to this, the usual practice was to form pills from wetted powders which were rolled out rather like pastry, cut to size and then 'balled' by rolling.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
